CAPARELLO, CHIARA
 Distribuzione geografica
Continente #
NA - Nord America 1.118
EU - Europa 422
AS - Asia 203
AF - Africa 56
OC - Oceania 9
Totale 1.808
Nazione #
US - Stati Uniti d'America 1.091
IT - Italia 127
CN - Cina 94
SE - Svezia 74
GB - Regno Unito 56
DE - Germania 53
SG - Singapore 51
BG - Bulgaria 44
CI - Costa d'Avorio 37
CA - Canada 27
VN - Vietnam 22
SN - Senegal 18
AT - Austria 14
FI - Finlandia 13
FR - Francia 13
KR - Corea 12
RU - Federazione Russa 11
TR - Turchia 10
AU - Australia 8
NL - Olanda 7
UA - Ucraina 6
HK - Hong Kong 4
IN - India 3
JP - Giappone 3
TW - Taiwan 2
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BJ - Benin 1
IR - Iran 1
KZ - Kazakistan 1
NZ - Nuova Zelanda 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.808
Città #
Woodbridge 167
Ann Arbor 142
Fairfield 118
Houston 105
Chandler 73
Ashburn 64
Sofia 44
Abidjan 37
New York 36
Seattle 36
Cambridge 34
Beijing 31
Princeton 31
Wilmington 29
Lancaster 24
Santa Clara 24
Ottawa 23
Pisa 22
London 20
Boardman 19
Florence 19
Dakar 18
Frankfurt am Main 18
Lawrence 18
Dearborn 17
Des Moines 15
Serra 15
Medford 14
Singapore 14
Vienna 14
Düsseldorf 11
Istanbul 8
Nanjing 8
Shenyang 8
Fuzhou 7
Iowa City 6
Los Angeles 6
Shanghai 6
Columbus 5
Hebei 5
Wuhan 5
Hong Kong 4
Milan 4
Redwood City 4
Bremen 3
Hefei 3
Phoenix 3
Pistoia 3
San Diego 3
Seacroft 3
Canino 2
Dong Ket 2
Grafing 2
Jiaxing 2
Massa 2
Montréal 2
Norwalk 2
Perth 2
Positano 2
Savona 2
Seoul 2
Strasbourg 2
Toronto 2
Almaty 1
Bari 1
Bratislava 1
Bucharest 1
Buffalo 1
Campi Bisenzio 1
Canberra 1
Castell'azzara 1
Castelnuovo Rangone 1
Changsha 1
Chengdu 1
Chicago 1
Chiesina Uzzanese 1
Cotonou 1
Daejeon 1
Dallas 1
Esslingen am Neckar 1
Ferrara 1
Freiburg 1
Guangzhou 1
Göttingen 1
Helsinki 1
Jinhua 1
Kunming 1
Leawood 1
Munich 1
New Bedfont 1
Newhall 1
Ninh Binh 1
Notre Dame 1
Ogden 1
Piombino 1
Prato 1
Pune 1
Quanzhou 1
Rotterdam 1
San Giuliano Terme 1
Totale 1.409
Nome #
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 244
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 131
Second-line therapy for advanced pancreatic cancer: Evaluation of prognostic factors and review of current literature 129
Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer? 127
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors 114
Correlation between LDH levels and response to sorafenib in HCC patients: An analysis of the ITA.LI.CA database 109
Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. 106
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction 102
Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol 99
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data 95
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer 95
Prognostic model for patients (PTS) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (Mfolfirinox) 86
Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (PTS) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? 82
Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: An AGEO prospective multicentre cohort' 81
Pharmacoepigenetics in gastrointestinal tumors: MGMT methylation and beyond 77
Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense? 72
Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients. 65
Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer 50
Totale 1.864
Categoria #
all - tutte 5.486
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.486


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020185 0 0 0 0 25 36 29 24 27 17 20 7
2020/202197 4 6 5 5 5 4 4 9 8 21 3 23
2021/2022193 2 6 4 5 43 24 8 6 11 5 16 63
2022/2023301 25 56 20 12 20 33 2 8 90 3 27 5
2023/2024152 5 10 20 2 23 33 19 7 1 6 9 17
2024/202588 0 19 20 27 22 0 0 0 0 0 0 0
Totale 1.864